Head-to-head clinical trials evaluating 1656 patients

OPERA I and II study design

The efficacy and safety of OCREVUS were studied vs Rebif in 2 double-blind, double-dummy trials evaluating more than 1600 patients for 2 years.

MRI and clinical results vs Rebif

RMS clinical and MRI efficacy

OCREVUS demonstrated superior clinical and MRI results vs Rebif over 2 years.

Safety profile in RMS studies

OCREVUS safety profile for RMS

The safety of OCREVUS was studied and demonstrated in OPERA I and OPERA II. Data from a follow-up, open-label extension (OLE) study is also shown. Learn about the potential for adverse reactions, including infections, IRRs, and other serious adverse events.